Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732082 · ClinicalTrials.gov registry record · Phase 1
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00732082 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT00732082, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine. IMP321 is a synthetic protein (made in the laboratory to simulate a protein that your body makes on its own) and was designed to stimulate the immune system with the overall objective of improving the body's capacity to react to your pancreas cancer.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL LAG-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732082
The ClinicalTrials.gov registry entry for NCT00732082 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00732082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732082 about?
NCT00732082 is a clinical study titled "Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer". The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine. IMP321 is a synthetic protein (made in the laboratory to simulate a protein that your body makes on its own) and was designed to stimulate...
What is the current status of trial NCT00732082?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2009-02. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00732082?
The interventions under investigation include: Gemcitabine (DRUG), LAG-3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00732082?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.